Congress expands cancer testing access for Medicare, Medicaid patients
H.R. 1620 — Finn Sawyer Access to Cancer Testing Act · Filed by Doris Matsui (D-CA) · 13 cosponsors · Introduced Feb 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare and Medicaid coverage for advanced cancer diagnostic tests—including genetic sequencing and DNA analysis—by requiring these tests to be covered at 80% of cost (or 100% if billed directly to Medicare) starting January 1, 2027. It also mandates coverage under CHIP and funds a public education program on genomic testing for doctors and patients.
Why we flagged it
The bill's primary function is to mandate public insurance coverage for advanced cancer diagnostic tests. While it bears a person's name (Finn Sawyer), the legislation itself is protective—expanding access to diagnostic tools for cancer patients—not a vanity provision honoring the namesake.
What the text implies
- The 6-month implementation window and January 1, 2027 effective date create a lag period during which tests remain uncovered, potentially delaying diagnosis for uninsured or underinsured patients.
- Frequency limits (once at diagnosis, once at recurrence, as needed for treatment planning) may restrict access to repeat testing if clinical judgment suggests more frequent monitoring is warranted, creating potential disputes over medical necessity.
The full analysis lists 5 implications of this text.
Who stands to gain
clinical laboratory companies; genomic testing providers; genetic counseling services